Last reviewed · How we verify
AST-726 Low dose
AST-726 is a low-dose drug that targets a specific molecular pathway.
AST-726 is a low-dose drug that targets a specific molecular pathway. Used for Phase 2 clinical trials for AST-726 are ongoing, but specific indications have not been disclosed..
At a glance
| Generic name | AST-726 Low dose |
|---|---|
| Sponsor | Ariston Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
While the exact mechanism of AST-726 is not well-documented, it is believed to modulate the activity of a key enzyme involved in the disease process.
Approved indications
- Phase 2 clinical trials for AST-726 are ongoing, but specific indications have not been disclosed.
Common side effects
- Unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |